SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Pedersen Maria) "

Sökning: WFRF:(Pedersen Maria)

Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
61.
  •  
62.
  •  
63.
  • Antonescu, Irina E., et al. (författare)
  • Acamprosate Is a Substrate of the Human Organic Anion Transporter (OAT) 1 without OAT3 Inhibitory Properties : Implications for Renal Acamprosate Secretion and Drug-Drug Interactions
  • 2020
  • Ingår i: Pharmaceutics. - : MDPI. - 1999-4923 .- 1999-4923. ; 12:4
  • Tidskriftsartikel (refereegranskat)abstract
    • Acamprosate is an anionic drug substance widely used in treating symptoms of alcohol withdrawal. It was recently shown that oral acamprosate absorption is likely due to paracellular transport. In contrast, little is known about the eliminating mechanism clearing acamprosate from the blood in the kidneys, despite the fact that studies have shown renal secretion of acamprosate. The hypothesis of the present study was therefore that renal organic anion transporters (OATs) facilitate the renal excretion of acamprosate in humans. The aim of the present study was to establish and apply OAT1 (gene product of SLC22A6) and OAT3 (gene product of SLC22A8) expressing cell lines to investigate whether acamprosate is a substrate or inhibitor of OAT1 and/or OAT3. The studies were performed in HEK293-Flp-In cells stably transfected with SLC22A6 or SLC22A8. Protein and functional data showed that the established cell lines are useful for studying OAT1- and OAT3-mediated transport in bi-laboratory studies. Acamprosate inhibited OAT1-mediated p-aminohippuric acid (PAH) uptake but did not inhibit substrate uptake via OAT3 expressing cells, neither when applied concomitantly nor after a 3 h preincubation with acamprosate. The uptake of PAH via OAT1 was inhibited in a competitive manner by acamprosate and cellular uptake studies showed that acamprosate is a substrate for OAT1 with a K-m-value of approximately 700 mu M. Probenecid inhibited OAT1-mediated acamprosate uptake with a K-i-value of approximately 13 mu M, which may translate into an estimated clinically significant DDI index. In conclusion, acamprosate was identified as a substrate of OAT1 but not OAT3.
  •  
64.
  • Baliakas, Panagiotis, et al. (författare)
  • Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study
  • 2014
  • Ingår i: Lancet Haematology. - : Elsevier. - 2352-3026. ; 1:2, s. 74-84
  • Tidskriftsartikel (refereegranskat)abstract
    • Background About 30% of cases of chronic lymphocytic leukaemia (CLL) carry quasi-identical B-cell receptor immunoglobulins and can be assigned to distinct stereotyped subsets. Although preliminary evidence suggests that B-cell receptor immunoglobulin stereotypy is relevant from a clinical viewpoint, this aspect has never been explored in a systematic manner or in a cohort of adequate size that would enable clinical conclusions to be drawn. Methods For this retrospective, multicentre study, we analysed 8593 patients with CLL for whom immunogenetic data were available. These patients were followed up in 15 academic institutions throughout Europe (in Czech Republic, Denmark, France, Greece, Italy, Netherlands, Sweden, and the UK) and the USA, and data were collected between June 1, 2012, and June 7, 2013. We retrospectively assessed the clinical implications of CLL B-cell receptor immunoglobulin stereotypy, with a particular focus on 14 major stereotyped subsets comprising cases expressing unmutated (U-CLL) or mutated (M-CLL) immunoglobulin heavy chain variable genes. The primary outcome of our analysis was time to first treatment, defined as the time between diagnosis and date of first treatment. Findings 2878 patients were assigned to a stereotyped subset, of which 1122 patients belonged to one of 14 major subsets. Stereotyped subsets showed significant differences in terms of age, sex, disease burden at diagnosis, CD38 expression, and cytogenetic aberrations of prognostic significance. Patients within a specific subset generally followed the same clinical course, whereas patients in different stereotyped subsets-despite having the same immunoglobulin heavy variable gene and displaying similar immunoglobulin mutational status-showed substantially different times to first treatment. By integrating B-cell receptor immunoglobulin stereotypy (for subsets 1, 2, and 4) into the well established Dohner cytogenetic prognostic model, we showed these, which collectively account for around 7% of all cases of CLL and represent both U-CLL and M-CLL, constituted separate clinical entities, ranging from very indolent (subset 4) to aggressive disease (subsets 1 and 2). Interpretation The molecular classification of chronic lymphocytic leukaemia based on B-cell receptor immunoglobulin stereotypy improves the Dohner hierarchical model and refines prognostication beyond immunoglobulin mutational status, with potential implications for clinical decision making, especially within prospective clinical trials.
  •  
65.
  •  
66.
  • Baliakas, Panagiotis, et al. (författare)
  • Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations.
  • 2015
  • Ingår i: Blood. - : American Society of Hematology. - 1528-0020 .- 0006-4971. ; 125:5, s. 856-859
  • Tidskriftsartikel (refereegranskat)abstract
    • An unresolved issue in chronic lymphocytic leukemia (CLL) is whether IGHV3-21 gene usage, in general, or the expression of stereotyped B-cell receptor immunoglobulin defining subset #2 (IGHV3-21/IGLV3-21), in particular, determines outcome for IGHV3-21-utilizing cases. We reappraised this issue in 8593 CLL patients of whom 437 (5%) used the IGHV3-21 gene with 254/437 (58%) classified as subset #2. Within subset #2, immunoglobulin heavy variable (IGHV)-mutated cases predominated, whereas non-subset #2/IGHV3-21 was enriched for IGHV-unmutated cases (P = .002). Subset #2 exhibited significantly shorter time-to-first-treatment (TTFT) compared with non-subset #2/IGHV3-21 (22 vs 60 months, P = .001). No such difference was observed between non-subset #2/IGHV3-21 vs the remaining CLL with similar IGHV mutational status. In conclusion, IGHV3-21 CLL should not be axiomatically considered a homogeneous entity with adverse prognosis, given that only subset #2 emerges as uniformly aggressive, contrasting non-subset #2/IGVH3-21 patients whose prognosis depends on IGHV mutational status as the remaining CLL.
  •  
67.
  • Bentley, Amy R., et al. (författare)
  • Multi-ancestry genome-wide gene-smoking interaction study of 387,272 individuals identifies new loci associated with serum lipids
  • 2019
  • Ingår i: Nature Genetics. - : Nature Publishing Group. - 1061-4036 .- 1546-1718. ; 51:4, s. 636-
  • Tidskriftsartikel (refereegranskat)abstract
    • The concentrations of high- and low-density-lipoprotein cholesterol and triglycerides are influenced by smoking, but it is unknown whether genetic associations with lipids may be modified by smoking. We conducted a multi-ancestry genome-wide gene-smoking interaction study in 133,805 individuals with follow-up in an additional 253,467 individuals. Combined meta-analyses identified 13 new loci associated with lipids, some of which were detected only because association differed by smoking status. Additionally, we demonstrate the importance of including diverse populations, particularly in studies of interactions with lifestyle factors, where genomic and lifestyle differences by ancestry may contribute to novel findings.
  •  
68.
  • Broms, Gabriella, et al. (författare)
  • Anti-TNF treatment during pregnancy and birth outcomes : Apopulation-based study from Denmark, Finland, and Sweden
  • 2020
  • Ingår i: Pharmacoepidemiology and Drug Safety. - 1053-8569 .- 1099-1557. ; 29:3, s. 316-327
  • Tidskriftsartikel (refereegranskat)abstract
    • Purpose: To study the risk of preterm birth, caesarean section, and small for gestational age after anti-tumor necrosis factor agent treatment (anti-TNF) in pregnancy.Methods: Population-based study including women with inflammatory bowel disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and psoriasis, and their infants born 2006 to 2013 from the national health registers in Denmark, Finland, and Sweden. Women treated with anti-TNF were compared with women with nonbiologic systemic treatment. Adalimumab, etanercept, and infliximab were compared pairwise. Continuation of treatment in early pregnancy was compared with discontinuation. Odds ratios with 95% confidence intervals were calculated in logistic regression models adjusted for country and maternal characteristics.Results: Among 1 633 909 births, 1027 infants were to women treated with anti-TNF and 9399 to women with nonbiologic systemic treatment. Compared with non-biologic systemic treatment, women with anti-TNF treatment had a higher risk of preterm birth, odds ratio 1.61 (1.29-2.02) and caesarean section, 1.57 (1.35-1.82). The odds ratio for small for gestational age was 1.36 (0.96-1.92). In pairwise comparisons, infliximab was associated with a higher risk of severely small for gestational age for inflammatory joint and skin diseases but not for inflammatory bowel disease. Discontinuation of anti-TNF had opposite effects on preterm birth for inflammatory bowel disease and inflammatory joint and skin diseases.Conclusions: Anti-TNF agents were associated with increased risks of preterm birth, caesarean section, and small for gestational age. However, the diverse findings across disease groups may indicate an association related to the underlying disease activity, rather than to agent-specific effects.
  •  
69.
  •  
70.
  • Byhamre, Marja Lisa, et al. (författare)
  • Swedish snus use is associated with mortality : a pooled analysis of eight prospective studies
  • 2020
  • Ingår i: International Journal of Epidemiology. - : Oxford University Press. - 0300-5771 .- 1464-3685.
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: The health consequences of the use of Swedish snus, including its relationship with mortality, have not been fully established. We investigated the relationship between snus use and all-cause and cause-specific mortality (death due to cardiovascular diseases, cancer diseases and all other reasons, respectively) in a nationwide collaborative pooling project.METHODS: We followed 169 103 never-smoking men from eight Swedish cohort studies, recruited in 1978-2010. Shared frailty models with random effects at the study level were used in order to estimate adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) of mortality associated with snus use.RESULTS: Exclusive current snus users had an increased risk of all-cause mortality (aHR 1.28, 95% CI 1.20-1.35), cardiovascular mortality (aHR 1.27, 95% CI 1.15-1.41) and other cause mortality (aHR 1.37, 95% CI 1.24-1.52) compared with never-users of tobacco. The risk of cancer mortality was also increased (aHR 1.12, 95% CI 1.00-1.26). These mortality risks increased with duration of snus use, but not with weekly amount.CONCLUSIONS: Snus use among men is associated with increased all-cause mortality, cardiovascular mortality, with death from other causes and possibly with increased cancer mortality.
  •  
Skapa referenser, mejla, bekava och länka
Typ av publikation
tidskriftsartikel (201)
konferensbidrag (15)
forskningsöversikt (4)
rapport (3)
bokkapitel (3)
bok (2)
visa fler...
doktorsavhandling (1)
visa färre...
Typ av innehåll
refereegranskat (211)
övrigt vetenskapligt (18)
Författare/redaktör
Pedersen, Nancy L (62)
Pedersen, NL (47)
Wareham, Nicholas J (42)
Loos, Ruth J F (40)
Uitterlinden, Andre ... (39)
McCarthy, Mark I (38)
visa fler...
Mohlke, Karen L (38)
Esko, Tonu (36)
Van Duijn, Cornelia ... (34)
Boehnke, Michael (34)
Jackson, Anne U. (34)
Franks, Paul W (33)
Morris, Andrew P (33)
Lindgren, Cecilia M. (33)
Boomsma, Dorret I. (32)
Laakso, Markku (32)
Langenberg, Claudia (32)
Barroso, Ines (32)
Kuusisto, Johanna (31)
Luan, Jian'an (31)
Deloukas, Panos (30)
Harris, Tamara B (30)
Hayward, Caroline (30)
Salomaa, Veikko (29)
Ridker, Paul M. (29)
Chasman, Daniel I. (29)
Scott, Robert A (29)
Boerwinkle, Eric (29)
Lakka, Timo A. (29)
Perola, Markus (28)
Lind, Lars (28)
Wilson, James F. (28)
Stefansson, Kari (28)
Magnusson, Patrik K ... (27)
Laakso, M (27)
Boehnke, M (27)
Tuomilehto, Jaakko (27)
Metspalu, Andres (27)
Palmer, Colin N. A. (27)
Rudan, Igor (27)
Ingelsson, Erik (26)
Ingelsson, E (26)
Samani, Nilesh J. (26)
Feitosa, Mary F. (26)
Stringham, Heather M ... (26)
Langenberg, C. (25)
Loos, RJF (25)
Stancáková, Alena (25)
Hayward, C. (25)
Kanoni, Stavroula (25)
visa färre...
Lärosäte
Lunds universitet (81)
Uppsala universitet (71)
Karolinska Institutet (52)
Göteborgs universitet (46)
Umeå universitet (41)
Linköpings universitet (14)
visa fler...
Stockholms universitet (10)
Chalmers tekniska högskola (10)
Jönköping University (7)
Mittuniversitetet (7)
Örebro universitet (5)
Högskolan i Halmstad (5)
Kungliga Tekniska Högskolan (4)
Sveriges Lantbruksuniversitet (4)
Linnéuniversitetet (3)
Malmö universitet (2)
Södertörns högskola (2)
Gymnastik- och idrottshögskolan (2)
Luleå tekniska universitet (1)
Naturvårdsverket (1)
Högskolan Dalarna (1)
visa färre...
Språk
Engelska (224)
Svenska (2)
Norska (1)
Italienska (1)
Odefinierat språk (1)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (138)
Naturvetenskap (57)
Samhällsvetenskap (18)
Teknik (10)
Lantbruksvetenskap (6)
Humaniora (2)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy